Díaz García, ClaudioSerrano Villar, SergioGarcía Ruiz de Morales, Alejandro G.Güerri Fernández, RobertPérez Somarriba, JuncalSánchez Palomino, SonsolesSuárez García, InésHernández Gutiérrez, CristinaDalmau, DavidMoreno, Santiagoet al.2025-11-072025-11-072025Díaz-García, C., Serrano-Villar, S., G. García-Ruiz De Morales, A., Güerri-Fernández, R., Pérez-Somarriba, J., Sánchez Palomino, S., Suárez-García, I., Hernández Gutiérrez, C., Dalmau Juanola, D., Moreno, S., Moreno, E., & Martínez-Sanz, J. (2025). Two or three? Clinical and proteomic perspectives on dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide as initial hiv treatment. Open Forum Infectious Diseases, 12(11), ofaf626. https://doi.org/10.1093/ofid/ofaf6262328-8957https://hdl.handle.net/11268/16446While triple-drug regimens (3DR) have long been the standard of care for HIV infection, two-drug regimens (2DR), particularly dolutegravir/lamivudine (DTG/3TC), have emerged as viable first-line options. However, there is limited understanding of how baseline clinical profiles associated with regimen choice relate to underlying inflammatory states and long-term immune trajectories. Regimen selection was associated with baseline disease severity and inflammatory burden. Despite being used in patients with more advanced profiles, BIC/F/TAF effectively reduced systemic inflammation over 2 years. Both regimens attenuated inflammatory activity, though with distinct trajectories that may carry implications for immune recovery and long-term outcomes.engAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Antirretroviralesjournal article10.1093/ofid/ofaf626open accessCiencias médicasPolítica de la saludBiotecnologíaGoal 3: Ensure healthy lives and promote well-being for all at all agesGoal 9: Build resilient infrastructure, promote sustainable industrialization and foster innovation